Tumor necrosis factor-α reduces adiponectin production by decreasing transcriptional activity of peroxisome proliferator-activated receptor-γ in calf adipocytes

被引:4
|
作者
Yu, Hao [1 ]
Gao, Xinxing [1 ]
Ge, Qilai [1 ]
Tai, Wenjun [1 ]
Hao, Xue [1 ]
Shao, Qi [1 ]
Fang, Zhiyuan [1 ]
Chen, Meng [1 ]
Song, Yuxiang [1 ]
Gao, Wenwen [1 ]
Liu, Guowen [1 ]
Du, Xiliang [1 ]
Li, Xinwei [1 ]
机构
[1] Jilin Univ, Coll Vet Med, State Key Lab Zoonot Dis, Key Lab Zoonosis Res, 5333 Xian Rd, Changchun 130062, Jilin, Peoples R China
基金
中国国家自然科学基金;
关键词
ent dairy cows; TNF-& alpha; adiponectin; PPAR & gamma; transition period; SUBCUTANEOUS ADIPOSE-TISSUE; PPAR-GAMMA; INSULIN-RESISTANCE; DSBA-L; TRANSITION PERIOD; LIPID-METABOLISM; GENE-EXPRESSION; EARLY LACTATION; SECRETION; DIFFERENTIATION;
D O I
10.3168/jds.2022-22919
中图分类号
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号
0905 ;
摘要
Adiponectin (encoded by ADIPOQ) is an adipokine that orchestrates energy homeostasis by modulating glucose and fatty acid metabolism in peripheral tissues. During the periparturient period, dairy cows often develop adipose tissue inflammation and decreased tumor necrosis factor-a (TNF-a) plays a pivotal role in regulating the endocrine functions of adipocytes, but whether it affects adiponectin production in calf adipocytes remains obscure. Thus, the present study aimed to determine whether TNF-a could affect adiponectin production in calf adipocytes and to identify the underlying mechanism. Adipocytes isolated from Holstein calves were differentiated and used for (1) BODIPY493/503 staining; (2) treatment with 0.1 ng/ receptor-? (PPARG) small interfering RNA for 48 TNF-a for 24 h; and (4) overexpression of PPARG for mL TNF-a for 24 h. After differentiation, obvious lipid droplets and secretion of adiponectin were observed in adipocytes. Treatment with TNF-a did not alter mRNA abundance of ADIPOQ but reduced the total of mRNA abundance of endoplasmic reticulum (ER)/ forming oxidoreductase A-like protein (GSTK1) were downregulated in TNF-a-treated adipocytes, while 78-kDa glucose-regulated protein and Golgi-localizing ?-adaptin ear homology domain ARF binding protein-1 were unaltered. Moreover, TNF-a diminished nuclear translocation of PPAR? and downregulated mRNA abundance of PPARG and its downstream target gene fatty acid synthase, suggesting that TNF-a suppressed the transcriptional activity of PPAR?. In the absence of TNF-a, overexpression of PPARG enhanced the total and HMW adiponectin content in supernatant and upregulated the mRNA abundance of ADIPOQ, ERP44, ERO1A, and GSTK1 in adipocytes. However, knockdown of PPARG reduced the total and HMW adiponectin content in supernatant and downregulated the mRNA abundance of ADIPOQ, ERP44, ERO1A, and GSTK1 in adipocytes. In the presence of TNF-a, overexpression of PPARG decreased, while knockdown of PPARG further exacerbated TNF-a-induced reduc-tions in total and HMW adiponectin secretion and gene expression of ERP44, ERO1A, and GSTK1. Overall, TNF-a reduces adiponectin assembly in the calf adipo-cyte, which may be partly mediated by attenuation of PPAR? transcriptional activity. Thus, locally elevated levels of TNF-a in adipose tissue may be one reason for the decrease in circulating adiponectin in periparturi-ent dairy cows.
引用
收藏
页码:5182 / 5195
页数:14
相关论文
共 50 条
  • [21] Activation of peroxisome proliferator-activated receptor-α enhances fatty acid oxidation in human adipocytes
    Lee, Joo-Young
    Hashizaki, Hikari
    Goto, Tsuyoshi
    Sakamoto, Tomoya
    Takahashi, Nobuyuki
    Kawada, Teruo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 407 (04) : 818 - 822
  • [22] Peroxisome Proliferator-Activated Receptor-α Control of Lipid and Glucose Metabolism in Human White Adipocytes
    Ribet, Carole
    Montastier, Emilie
    Valle, Carine
    Bezaire, Veronic
    Mazzucotelli, Anne
    Mairal, Aline
    Viguerie, Nathalie
    Langin, Dominique
    ENDOCRINOLOGY, 2010, 151 (01) : 123 - 133
  • [23] The ribosomal protein rpL11 associates with and inhibits the transcriptional activity of peroxisome proliferator-activated receptor-α
    Gray, JP
    Davis, JW
    Gopinathan, L
    Leas, TL
    Nugent, CA
    Vanden Heuvel, JP
    TOXICOLOGICAL SCIENCES, 2006, 89 (02) : 535 - 546
  • [24] Leptin regulation of peroxisome proliferator-activated receptor-γ, tumor necrosis factor, and uncoupling protein-2 expression in adipose tissues
    Qian, H
    Hausman, GJ
    Compton, MM
    Azain, MJ
    Hartzell, DL
    Baile, CA
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 246 (03) : 660 - 667
  • [25] What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance?
    Boyle, PJ
    CLINICAL CARDIOLOGY, 2004, 27 (07) : 11 - 16
  • [26] Transcriptional Modulation of the Immune Response by Peroxisome Proliferator-Activated Receptor-α Agonists in Autoimmune Disease
    Gocke, Anne R.
    Hussain, Rehana Z.
    Yang, Yuhong
    Peng, Haiyan
    Weiner, Jeffrey
    Ben, Li-Hong
    Drew, Paul D.
    Stuve, Olaf
    Lovett-Racke, Amy E.
    Racke, Michael K.
    JOURNAL OF IMMUNOLOGY, 2009, 182 (07): : 4479 - 4487
  • [27] Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production
    Hwang, JN
    Kleinhenz, DJ
    Lassègue, B
    Griendling, KK
    Dikalov, S
    Hart, CM
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2005, 288 (04): : C899 - C905
  • [28] A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia
    Shimazu, T
    Inoue, I
    Araki, N
    Asano, Y
    Sawada, M
    Furuya, D
    Nagoya, H
    Greenberg, JH
    STROKE, 2005, 36 (02) : 353 - 359
  • [29] Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-α activity
    Schupp, M
    Janke, J
    Clasen, R
    Unger, T
    Kintscher, U
    CIRCULATION, 2004, 109 (17) : 2054 - 2057
  • [30] Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-γ-dependent mechanism in mice
    Neschen, S
    Morino, K
    Rossbacher, JC
    Pongratz, RL
    Cline, GW
    Sono, S
    Gillum, M
    Shulman, GI
    DIABETES, 2006, 55 (04) : 924 - 928